Table 1.
Demographic characteristics of study patients according to the presence of NAFLD.
| Total (n = 321) | NAFLD (–) (n = 115) | NAFLD (+) (n = 206) | P-value | |
|---|---|---|---|---|
| DEMOGRAPHIC VARIABLES | ||||
| Age, years | 67.0 [56.0 to 74.0] | 70.0 [58.5 to 76.0] | 66.0 [56.0 to 73.0] | 0.011 |
| Sex, men | 191 (59.5) | 66 (57.4) | 125 (60.7) | 0.648 |
| Hypertension | 232 (72.3) | 74 (64.3) | 158 (76.7) | 0.025 |
| Diabetes | 105 (32.7) | 33 (28.7) | 72 (35.0) | 0.307 |
| Dyslipidemia | 56 (17.4) | 13 (11.3) | 43 (20.9) | 0.044 |
| Metabolic syndrome | 166 (51.7) | 44 (38.3) | 122 (59.2) | < 0.001 |
| Body mass index, kg/m2 | 23.6 [21.8 to 25.8] | 21.8 [20.0 to 23.3] | 24.6 [22.9 to 26.8] | < 0.001 |
| Smoker | 77 (24.0) | 36 (31.3) | 41 (19.9) | 0.031 |
| Ischemic heart disease | 118 (36.8) | 40 (34.8) | 78 (37.9) | 0.668 |
| Peripheral artery occlusive disease | 56 (17.4) | 21 (18.3) | 35 (17.0) | 0.893 |
| Atrial fibrillation | 27 (8.4) | 14 (12.2) | 13 (6.3) | 0.108 |
| STROKE VARIABLES | ||||
| NIHSS at admission | 2.0 [1.0 to 5.0] | 3.0 [1.0 to 6.0] | 2.0 [0.0 to 4.0] | 0.012 |
| TOAST classification (n = 290) | 0.364 | |||
| Cardioembolism | 107 (36.9) | 43 (40.2) | 64 (35.0) | |
| Large artery atherosclerosis | 39 (13.4) | 11 (10.3) | 28 (15.3) | |
| Lacunar | 13 (4.5) | 5 (4.7) | 8 (4.4) | |
| Other determined etiology | 18 (6.2) | 3 (2.8) | 15 (8.2) | |
| Negative evaluation | 37 (12.8) | 14 (13.1) | 23 (12.6) | |
| More than two causes | 76 (26.2) | 31 (29.0) | 45 (24.6) | |
| Duration of hospitalization | 6.0 [5.0 to 9.0] | 7.0 [5.0 to 10.0] | 6.0 [4.0 to 8.0] | 0.020 |
| Favorable mRS at 90 days (n = 289) | 231 (79.9) | 74 (70.5) | 157 (85.3) | 0.004 |
| LABORATORY VARIABLES | ||||
| Aspartate aminotransferase, μkat/L | 0.4 [0.3 to 0.5] | 0.4 [0.3 to 0.5] | 0.4 [0.3 to 0.5] | 0.441 |
| Alanine aminotransferase, μkat/L | 0.3 [0.2 to 0.4] | 0.3 [0.2 to 0.3] | 0.3 [0.2 to 0.5] | < 0.001 |
| Platelet count, × 103/mm3 | 229.0 [192.0 to 275.0] | 222.0 [181.0 to 276.0] | 237.0 [197.0 to 275.0] | 0.221 |
| Fasting blood glucose, mmol/L | 5.8 [5.2 to 7.1] | 5.6 [5.0 to 7.2] | 5.9 [−5.2 to 7.0] | 0.193 |
| eGFR, mL·min−1·1.73 m−2 | 89.0 [76.0 to 90.0] | 90.0 [80.0 to 90.0] | 88.5 [75.0 to 90.0] | 0.215 |
| Total cholesterol, mmol/L | 4.3 [3.7 to 5.0] | 4.2 [3.6 to 4.9] | 4.4 [3.7 to 5.1] | 0.260 |
| Triglyceride, mmol/L | 1.2 [0.8 to 1.6] | 1.0 [0.7 to 1.4] | 1.3 [−0.9 to 1.7] | < 0.001 |
| High-density lipoprotein, mmol/L | 1.1 [0.9 to 1.3] | 1.1 [1.0 to 1.3] | 1.0 [0.9 to 1.2] | 0.009 |
| Low-density lipoprotein, mmol/L | 2.6 [2.0 to 3.3] | 2.5 [2.0 to 3.0] | 2.6 [2.0 to 3.4] | 0.288 |
| LIVER VARIABLES | ||||
| Liver stiffness, kPa | 4.7 [4.0 to 6.1] | 4.6 [4.0 to 5.8] | 4.7 [4.0 to 6.3] | 0.750 |
| Advanced fibrosis, >8 kPa | 32 (10.0) | 11 (9.6) | 21 (10.2) | >0.999 |
| CAP, dB/m | 241.0 [207.0 to 275.0] | 197.0 [177.0 to 209.5] | 261.0 [242.0 to 289.0] | < 0.001 |
NAFLD, non-alcoholic fatty liver disease; NIHSS, National Institute of Health Stroke Scale; TOAST, Trial of ORG 10172 in Acute Stroke Treatment; mRS, modified Rankin scale; eGFR, estimated glomerular filtration rate; CAP, controlled attenuation parameter. Data are given as median [interquartile range] or number (%).